Hepatitis C, table 1, Prospective Study of InterferonTherapy for Compensated Cirrhotic Patients With Chronic Hepatitis Cby Monitoring Serum Hepatitis C RNA

Prospective Study of Interferon Therapy for Compensated Cirrhotic Patients With Chronic Hepatitis C by Monitoring Serum Hepatitis C RNA

table 1. Demographic Features of Patients

Parameters	Treatment		Total
Parameters	+16 Weeks	+32 Weeks	Total

Number of patients	37	36	157
Age (year old)	53.4 ± 9.3	57.7 ± 10.4	56.0 ± 8.8
Gender (male:female)	24:13	22:14	91:66
History of blood transfusion	16 (43%)	17 (47%)	73 (47%)
Duration after blood transfusion (years)	27.6 ± 10.6	30.8 ± 6.6	30.0 ± 8.3
Biochemical parameters
Albumin (g/dL)	3.9 ± 0.4	3.9 ± 0.4	4.0 ± 0.4
AST (IU/l) (SD, +SD)	90 (55-145)	85 (42-172)	82 (48-141)
ALT (IU/l) (SD, +SD)	110 (62-194)	99 (41-240)	95 (48-186)
Bilirubin (mg/dL) (SD, +SD)	0.79 (0.58-1.08)	0.83 (0.56-1.21)	0.83 (0.58-1.17)
Platelet count (10³/mm³)	121 ± 42	122 ± 46	116 ± 41
Virus characteristics
HCV RNA level (copies/mL)	10^6.69±1.29	10^6.44±0.95	10^6.90±1.01
HCV subtype
1b	27	21	124
2a	8	10	24
2b	1	3	5
Mixed	1	1	2
Missing	0	1	2

NOTE. Data are expressed as mean ± SD. Logarithmic transformation was performed on the variables of AST, ALT, and bilirubin.